永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 09-01 15:07:55

0.390

+0.000

0.00%

最高0.390	最低0.390	成交量2.00万
今开0.390	昨收0.390	日振幅0.00%
总市值2.41亿	流通市值2.41亿	总股本6.18亿
成交额7,800	换手率0.00%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.39,"timestamp":1788246475401,"preClose":0.39,"halted":0,"volume":20000,"delay":0,"changeRate":0,"floatShares":618000000,"shares":618000000,"eps":-0.48981612890579057,"marketStatus":"已收盘","change":0,"latestTime":"09-01 15:07:55","open":0.39,"high":0.39,"low":0.39,"amount":7800,"amplitude":0,"askPrice":0.395,"askSize":12000,"bidPrice":0.39,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.33318575939938055,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.39,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"volumeRatio":0.436681,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"1111865861","title":"永泰生物-B8月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1111865861","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111865861?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:42","pubTimestamp":1788252170,"startTime":"0","endTime":"0","summary":"永泰生物製藥有限公司于2026年9月1日发布截至2026年8月31日的股份变动月报表。报告显示，公司注册股本依旧为5,000,000美元，已发行股份总数617,500,800股，较上月底无新增发行或注销，股本结构维持稳定。在限售及激励方面，公司于首次公开发售前购股权计划项下，期末持有股份期权数量为9,872,850份，当月无增减变动，未因期权行使而新增发行任何股份。首次公开发售后购股权计划期末持有期权数量为0，亦无变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664088647","title":"2026版国家基药目录今起施行：4款国产创新药纳入，如何影响行业与大众？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664088647","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664088647?lang=zh_cn&edition=full","pubTime":"2026-09-01 07:16","pubTimestamp":1788218160,"startTime":"0","endTime":"0","summary":"9月1日，由国家卫生健康委、国家中医药局、国家疾控局三部门联合发布的2026版《国家基本药物目录》（简称“基药目录”）正式施行。时隔8年，基药目录再次迎来重磅扩容。官方消息显示，新版目录共收录药品794种，新增药品品种116种，包含化学药品和生物制品68种、中成药48种。调出原版目录内化学药品和生物制品2种，无中成药品种调出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860569178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860569178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LNGR","IBBQ","159992","BK1574","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048920","title":"A股医药中报收官，创新药企批量扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048920","media":"全球财说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048920?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:47","pubTimestamp":1788187620,"startTime":"0","endTime":"0","summary":"01中报收官，业绩分化创新药是本轮中报业绩变化最明显的方向之一。石药创新同样依靠BD兑现实现业绩反转。一条兑现路径是海外BD授权。大额BD的价值不只是改善当期利润表，即首付款可迅速补充现金储备，海外大型药企愿意支付较高金额本身也是对国产创新药研发能力的市场化验证。BD相关收入的持续兑现能力，仍是当前观察创新药企基本面的核心落脚点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-31/doc-iniqfqsp8765429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1161","LNGR","MEDX","BK1574","06978","KURE","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663787260","title":"英特集团：公司主要通过DTP专业药房，为创新药提供上市后的终端服务和患者管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2663787260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663787260?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:48","pubTimestamp":1788162490,"startTime":"0","endTime":"0","summary":"证券之星消息，英特集团(000411)08月31日在投资者关系平台上答复投资者关心的问题。投资者提问：你好懂秘：请问公司有没有为创新药提供商业化服务？英特集团回复：您好！公司主要通过DTP专业药房，为创新药提供上市后的终端服务和患者管理。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100017338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK0250","000411","159992","BK1161","BK0097","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663602828","title":"中国生物制药：创新药Kylo-11 I期临床数据在ESC 2026及《柳叶刀》公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2663602828","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663602828?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:03","pubTimestamp":1788134617,"startTime":"0","endTime":"0","summary":"中国生物制药：创新药Kylo-11 I期临床数据在ESC 2026及《柳叶刀》公布","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313859573668.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313859573668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","BK1161","BK1521","IBBQ","LNGR","IE00BZ08YT58.USD","01177","BK1589","BK1191","IE00BZ08YS42.EUR","159992","IE00BZ08YR35.GBP","MEDX","BK1574","06978","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663028341","title":"股市必读：上海谊众新发布《上海谊众药业股份有限公司关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663028341","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663028341?lang=zh_cn&edition=full","pubTime":"2026-08-31 07:47","pubTimestamp":1788133628,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，上海谊众报收于40.5元，下跌6.36%，换手率3.22%，成交量6.64万手，成交额2.73亿元。当日关注点交易信息汇总：8月28日主力资金净流入492.26万元，占总成交额1.8%。公司公告汇总：上海谊众将于2026年9月16日15:00-17:00参加科创板创新药行业集体业绩说明会，董事长/总经理周劲松等高管将出席并回应投资者提问。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱提交问题。说明会后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK1574","BK1161","688091","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663236720","title":"私募人士观点现分歧 投资主线或正在酝酿","url":"https://stock-news.laohu8.com/highlight/detail?id=2663236720","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663236720?lang=zh_cn&edition=full","pubTime":"2026-08-31 07:10","pubTimestamp":1788131440,"startTime":"0","endTime":"0","summary":"【私募人士观点现分歧 投资主线或正在酝酿】近日，东方港湾创始人但斌、日斗投资创始人王文、神农投资创始人陈宇、知名投资人段永平等私募人士，公开发布了最新投资观点和感悟。可以看到，私募人士之间的观点分歧，不仅涉及科技领域的机会甄别，更关乎市场投资主线的判断。对于AI、券商、创新药、龙头白酒、保险等方向，私募人士看法不一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202608313859539058.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202608313859539058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["CHAT","06978","BK1574","QTOC","ARTY","VTHR","MEDX","IBBQ","BK1161","LNGR","AIPO","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004513","title":"每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004513","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663004513?lang=zh_cn&edition=full","pubTime":"2026-08-30 10:13","pubTimestamp":1788055988,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，首药控股报收于34.94元，较上周的37.71元下跌7.35%。本周，首药控股8月24日盘中最高价报38.45元。股本股东变化截至2026年6月30日，公司股东户数为5917.0户，较3月31日增加328.0户，增幅5.87%。户均持股数量由上期的2.66万股降至2.51万股，户均持股市值为83.97万元。公司持续推进“提质增效重回报”行动方案，进入研发与商业化协同推进新阶段，经营亏损大幅收窄，财务结构稳健，募集资金使用规范。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK1161","BK0239","688197","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663014574","title":"股价月内翻倍后高位回调，百花医药回应：公司创新药CRO占比很小","url":"https://stock-news.laohu8.com/highlight/detail?id=2663014574","media":"中证金牛座","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663014574?lang=zh_cn&edition=full","pubTime":"2026-08-29 13:34","pubTimestamp":1787981640,"startTime":"0","endTime":"0","summary":"公司主要做仿制药CRO，创新药CRO占比很小。相比仿制药，创新药投入大、回报不及预期的风险也大。公司属于药厂的上游环节，CRO业务对接药厂。仿制药CRO行业竞争加剧，属于买方市场，公司需要主动去找业务，订单单价不如往年高。此外，百花医药当晚还发布股东减持股份计划的公告。公告显示，公司持股5%以下股东李建城因自身资金需求，拟于公告披露之日起15个交易日后的3个月内，通过集中竞价方式减持其持有的公司股份100万股。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-08-29/doc-inipyfhx9285135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK0102","BK1574","IBBQ","LNGR","159992","MEDX","600721","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662099745","title":"上海谊众（688091）披露将参加科创板2026年半年度创新药行业集体业绩说明会，8月28日股价下跌6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662099745","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662099745?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:21","pubTimestamp":1787926908,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，上海谊众报收于40.5元，较前一交易日下跌6.36%，最新总市值为83.71亿元。该股当日开盘42.47元，最高42.77元，最低40.01元，成交额达2.73亿元，换手率为3.22%。公告显示，公司将于2026年9月16日15:00-17:00参加科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动方式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800054699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","159992","688091","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662105181","title":"一品红H1净利润大幅回升，痛风创新药AR882将迎关键收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662105181","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662105181?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:02","pubTimestamp":1787896928,"startTime":"0","endTime":"0","summary":"在全球医药产业加速创新转型的大势下，叠加我国“十五五”规划对生物医药战略性新兴产业的全面赋能，兼具自主知识产权与临床差异化价值的创新药，正成为驱动行业高质量发展的核心引擎。　　一品红正是这样一家聚焦儿童药与创新慢病药的创新型生物医药企业，同时公司更坚定推进创新药优先战略。据公开披露，报告期内公司实现营业收入4.92亿元，归母净利润达4.85亿元，同比大幅增长759.11%，成功扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260828/32351573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300723","159992","MEDX","06978","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037097","title":"同源康医药-B早盘高开近15% 创新药TY-9591片获批准附条件上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037097","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037097?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:35","pubTimestamp":1787880900,"startTime":"0","endTime":"0","summary":"模拟交易客户端同源康医药-B早盘高开近15%，截至发稿，股价上涨14.99%，现报7.825港元，成交额275.83万港元。8月27日晚，同源康医药公布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-28/doc-inipvrtx8899235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","MEDX","02410","BK1574","06978","BK1161","159938","IBBQ","09939","LNGR","159992","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037468","title":"港股异动 | 同源康医药-B(02410.HK)高开近15% 创新药TY-9591片获批准附条件上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037468?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:24","pubTimestamp":1787880257,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02410","BK1161","BK1515","06978","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032725","title":"国家医保局召开医保促进“十五五”医药产业高质量发展座谈会","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032725","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662032725?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:00","pubTimestamp":1787878842,"startTime":"0","endTime":"0","summary":"加大对创新药械和创新服务项目的支持","market":"hk","thumbnail":"https://img3.gelonghui.com/5a971-e4bc2669-8728-40d1-b85b-174c38b13f1a.jpg?guru_height=2595&guru_width=4630&guru_size=776778","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/5a971-e4bc2669-8728-40d1-b85b-174c38b13f1a.jpg?guru_height=2595&guru_width=4630&guru_size=776778"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6376571","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","MEDX","BK1515","LNGR","IBBQ","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701755","title":"业绩与临床双轮驱动，创新药板块持续走强还能火多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701755","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662701755?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:57","pubTimestamp":1787828223,"startTime":"0","endTime":"0","summary":"红星资本局8月27日消息，8月26日、27日，港股创新药指数（931787）连续上涨，康希诺生物（6185.HK）、信达生物（1801.HK）、翰森制药（3692.HK）等多只个股表现活跃，股价创出阶段新高。红星资本局注意到，市场交易的重心已经从此前海外重磅临床数据的情绪催化，切换至中报业绩的利润兑现与临床突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608273856626663.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608273856626663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","MEDX","LNGR","IBBQ","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706803","title":"长城基金梁福睿：下半年医药板块预计仍有结构性行情，看好以创新药为代表的高景气方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706803","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662706803?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:39","pubTimestamp":1787827140,"startTime":"0","endTime":"0","summary":"长城医药产业基金经理 梁福睿：医药板块自6月中旬以来经历了约两个月的上涨行情，主要原因可分为板块内部因素和板块外部因素。其中内部因素主要为：①以CXO、创新药和生命科学上游等为代表的医药高景气赛道产业趋势积极向好。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-27/doc-inipucst5884322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","IBBQ","159938","BK1515","LNGR","BK1161","159992","09939","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662779300","title":"海思科2026年半年报：创新药出海取得突破，管线临床与商业化仍存不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779300","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662779300?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:31","pubTimestamp":1787815911,"startTime":"0","endTime":"0","summary":"财报数据显示，报告期公司实现营业收入30.96亿元，同比增长54.71%；归母净利润8.51亿元，同比增长426.98%；扣非净利润7.52亿元，同比增长324.18%。业绩大幅跃升的核心驱动力在于创新药商业化加速与BD出海成果落地。展望未来，随着全球创新药竞争加剧及国内医保控费常态化，公司面临市场竞争与新药研发不确定性的双重挑战。尽管BD收入带来短期业绩爆发，但其可持续性依赖于后续管线的临床进展与商业化落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787795134537106176","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159992","BK1574","BK0028","BK0077","LNGR","BK1161","MEDX","06978","BK0033","BK0239","002653","BK0188","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662992722","title":"创新药反复活跃，后市怎么走？华宝基金港股通创新药ETF（520880）基金经理火线拆解行情逻辑！","url":"https://stock-news.laohu8.com/highlight/detail?id=2662992722","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662992722?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:20","pubTimestamp":1787800800,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝关注度持续升温。图：港股通创新药ETF华宝近6个月日K走势如何看待近期创新药行情？港股通创新药ETF华宝基金经理丰晨成最新解读来了，三个维度拆解行情逻辑。全链布局创新药，关注两大T+0交易利器：港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-27/doc-iniptnux9036538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1161","BK1574","MEDX","LNGR","159316","06978","FLHK","520880","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729721","title":"港股异动 | 翰森制药涨超12%，上半年纯利同比增长35.82%，创新药收入占比超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729721","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729721?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:43","pubTimestamp":1787794987,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，$翰森制药(03692)$(03692)涨超12%。消息面上，翰森制药发布2026年中期业绩，今年上半年，公司实现收入人民币83.04亿元(单位下同)，同比增加11.71%；母公司拥有人应占溢利42.58亿元，同比增加35.82%；每股盈利0.7元，拟派发中期股息每股28.5港仙，同比增长23.1%。上半年，创新药收入约人民币70.92亿元，占收入比例约 85.4%，已成为驱动该公司业绩可持续增长的核心动力。截至2026年6月30日止六个月内，集团正在进行的创新药临床试验超过七十项，分属超过四十个候选创新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486705.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药上半年纯利同比增长35.82%，创新药收入占比超85%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","MEDX","BK1161","BK1589","LNGR","BK1583","KCAI","IBBQ","06978","BK1191","159992","BK1574","BK4585","VXUS","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662297237","title":"港股异动 | 翰森制药(03692.HK)涨超10% 上半年纯利同比增长35.82% 创新药收入占比超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662297237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662297237?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:33","pubTimestamp":1787794433,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1191","06978","BK1574","03692","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0986},{"period":"3month","weight":-0.4658},{"period":"6month","weight":-0.834},{"period":"1year","weight":-0.926},{"period":"ytd","weight":-0.8669}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":-0.0123},{"period":"3month","weight":-0.0181},{"period":"6month","weight":0.0126},{"period":"1year","weight":0.0195},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.024873},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}